Immune checkpoint inhibitors vs any second‐line chemotherapy
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
- Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes onlyRR 0.35 [0.17, 0.72]2 studies · 1473 participantsLow